These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23359265)

  • 21. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
    Veldkamp AI; Weverling GJ; Lange JM; Montaner JS; Reiss P; Cooper DA; Vella S; Hall D; Beijnen JH; Hoetelmans RM
    AIDS; 2001 Jun; 15(9):1089-95. PubMed ID: 11416710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
    Elsherbiny D; Cohen K; Jansson B; Smith P; McIlleron H; Simonsson US
    Eur J Clin Pharmacol; 2009 Jan; 65(1):71-80. PubMed ID: 18751690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steady-state pharmacokinetics of lamivudine once-daily versus twice-daily dosing in Chinese HIV-infected patients.
    Ye M; Wang L; Fu Q; Zhu Z; Li P; Li T
    HIV Clin Trials; 2010; 11(4):230-7. PubMed ID: 20974578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial.
    Gozalo C; Gérard L; Loiseau P; Morand-Joubert L; Peytavin G; Molina JM; Dellamonica P; Becquemont L; Aboulker JP; Launay O; Verstuyft C;
    Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):513-20. PubMed ID: 21824325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver toxicity caused by nevirapine.
    González de Requena D; Núñez M; Jiménez-Nácher I; Soriano V
    AIDS; 2002 Jan; 16(2):290-1. PubMed ID: 11807315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.
    Calcagno A; D'Avolio A; Simiele M; Cusato J; Rostagno R; Libanore V; Baietto L; Siccardi M; Bonora S; Di Perri G
    Br J Clin Pharmacol; 2012 Jul; 74(1):134-40. PubMed ID: 22680342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
    Núñez M; González-Requena D; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2003 Mar; 19(3):187-8. PubMed ID: 12689410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis.
    Cammett AM; MacGregor TR; Wruck JM; Felizarta F; Miailhes P; Mallolas J; Piliero PJ
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4147-52. PubMed ID: 19620337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
    Battegay M; Arasteh K; Plettenberg A; Bogner JR; Livrozet JM; Witt MD; Mossdorf E; Yong CL; Zhang W; Macha S; Berger F; Stern J; Robinson P; Quinson AM
    Clin Ther; 2011 Sep; 33(9):1308-20. PubMed ID: 21872931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
    Martínez E; Blanco JL; Arnaiz JA; Pérez-Cuevas JB; Mocroft A; Cruceta A; Marcos MA; Milinkovic A; García-Viejo MA; Mallolas J; Carné X; Phillips A; Gatell JM
    AIDS; 2001 Jul; 15(10):1261-8. PubMed ID: 11426070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?
    Notter J; Bregenzer A; Vernazza P; Kahlert CR
    Swiss Med Wkly; 2019 Apr; 149():w20053. PubMed ID: 31017649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa.
    Mazanderani AH; Murray TY; Sherman GG; Snyman T; George J; Avenant T; Goga AE; Pepper MS; du Plessis N
    J Int AIDS Soc; 2019 Jun; 22(6):e25284. PubMed ID: 31215757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of nevirapine, stavudine and lamivudine in Indian HIV-infected children receiving generic fixed dose combinations.
    Mukherjee A; Singla M; Velpandian T; Sirohiwal A; Vajpayee M; Singh R; Kabra SK; Lodha R
    Indian Pediatr; 2014 Mar; 51(3):191-7. PubMed ID: 24736906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
    Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy.
    Stephan C; León W
    HIV Med; 2014 Feb; 15(2):124-8. PubMed ID: 24112515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
    Droste JA; Kearney BP; Hekster YA; Burger DM
    J Acquir Immune Defic Syndr; 2006 Jan; 41(1):37-43. PubMed ID: 16340471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.
    Matteelli A; Saleri N; Villani P; Bonkoungou V; Carvalho AC; Kouanda S; Sanou MJ; Simporé J; Monno L; Carosi G; Regazzi M; Dembele M
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):64-9. PubMed ID: 19731452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.